This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

Evelo Biosciences, Inc.
3/9/2021
Welcome to Avello Biosciences conference call to discuss the fourth quarter and full year 2020 financial results and business highlights. At this time, all participants are in listen-only mode. Following the formal remarks, we will open the call up for your questions. Please be advised that this call is being recorded at the company's request. At this time, I'd like to turn the call over to Jessica Catrone of Avello. Please proceed.
Thank you. This morning, we issued a press release that outlines the topics we plan to discuss today. This release is available at www.avelobio.com under the Investors tab. Today on our call, Simba Gill, Chief Executive Officer, Mark Bodmer, President of R&D and Chief Scientific Officer, and Jonathan Zung, Chief Development Officer, will review our fourth quarter and full year 2020 financial results and recent business highlights. Before we begin, I would like to remind everyone that statements made during this conference call that do not relate to matters of historical fact including statements about our objective and anticipated clinical milestones, the impact of any of our product candidates, and the timing and results of any clinical studies should be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are intended to be subject to the safe harbor protection provided by the Reform Act. Actual results could differ materially from those indicated by the forward-looking statements due to the impact of many factors. Participants are directed to the risk factors set forth in Avello's annual report on Form 10-K for the fiscal year ended December 31, 2020, and the company's other filings with the Securities and Exchange Commission. Any forward-looking statements made today speak only to Avello's operations as of today. Avello disclaims any duty to provide updates to its forward-looking statements even if subsequent events cause the company's views to change. It is now my pleasure to pass the call over to Simba.
Thank you, Jessica. Good morning, everyone, and thanks for joining. Over the last four years, we've generated clear preclinical and clinical data that showed the effects of our small intestinal axis or syntax medicines, investigational medicines designed to work within the small intestine to change inflammation and immunity throughout the body. Syntax medicines have the potential to be not only effective, but easy to take, safe and well tolerated, and with the ability to be manufactured at large scale and low cost. And over the last 18 months, we have reported a series of clinical successes with EDP 1815, our lead anti-inflammatory medicine candidate. EDP 1815 has shown clinical effects on Th1, Th2, and Th17-driven biology, the three major drivers of inflammatory disease, supporting the potential of EDP 1815 as a broadly acting, well-tolerated oral medicine that may resolve inflammation without immunosuppression. Most recently, in December and January, we presented positive results from a cohort of patients with atopic dermatitis in our Phase 1B clinical trial. And today, we are reporting a fifth set of positive clinical data with EDP 1815. Today's announcement relates to a human clinical experimental model of inflammation that evaluated a new, more concentrated formulation of EDP 1815. These new data suggest an ability to enhance the efficacy of EDP 1815. Mark will tell you the details of this in a moment. This is the time of great growth and progress for Avello as we execute on a series of clinical studies over the next year in preparation for phase three trials. Jonathan will tell you more about our clinical studies and plans later in the call. Importantly, EDP 1815 and our other inflammation programs EDP 1867 and EDP 2939 go far beyond dermatology in their potential, and we intend to expand into broader areas of inflammation, including the arthritis, asthma, and inflammatory bowel diseases. Beyond inflammation, we continue to develop our oncology program. Data from a preclinical study of EDP1908, a bacterial extracellular vesicle, was published at CITSE in November. EDP1908 has the potential to be a foundational immuno-oncology treatment in cancer. In building the company, we have expanded our leadership, hiring Jonathan Zung as Chief Development Officer to lead execution of our clinical development programs and the recent appointment of John Honaker to our board of directors. Both Jonathan and John had deep and highly successful track records in drug development, regulatory approval, and commercial launches across inflammation and oncology. We have also strengthened our balance sheet and have the capital to fund the company past the next wave of clinical milestones and into the third quarter of 2022. Our main objectives are, first, to complete a phase two trial of EDP1815 in psoriasis, to also initiate a phase two trial of EDP1815 in atopic dermatitis, and to begin preparations for phase three trials of EDP1815. The second objective is to continue to progress our current clinical pipeline beyond EDP1815 including EDP 1867, where we're looking to generate clinical results with a separate anti-inflammatory medicine. The third objective is to complete preclinical and manufacturing development of our inflammation and oncology extracellular vesicle drug candidates to be ready for clinical trials in 2022. I'd like to turn the call over to Mark, who will talk to you about data on EDP 1815, in a human experimental model of inflammation, and to Jonathan, who will then summarize our clinical plans. Mark, over to you.
You're reading a preview of the EVLO Q4 2020 earnings call.
Free account.